c-Met EGFR IGF-1R Pharmaceutical composition for combination therapy containing dual inhibitor of c-Met and EGFR and IGF-1R inhibitor

摘要

A pharmaceutical composition for co-administration for the prevention and/or treatment of cancer comprising a dual c-Met and EGFR inhibitor and an IGF-1R inhibitor as an active ingredient; overcome), and the use of IGF-IR as a marker of resistance to dual c-Met and EGFR inhibitors are provided.